BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
1/27/2019 7:04:05 AM | Browse: 1191 | Download: 1911
 |
Received |
|
2018-09-27 03:36 |
|
Peer-Review Started |
|
2018-09-27 04:25 |
|
First Decision by Editorial Office Director |
|
2018-10-16 15:16 |
|
Return for Revision |
|
2018-10-19 04:32 |
|
Revised |
|
2018-11-14 01:09 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2018-12-29 02:13 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2019-01-01 05:56 |
|
Articles in Press |
|
2019-01-01 05:56 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2019-01-24 09:03 |
|
Publish the Manuscript Online |
|
2019-01-27 07:04 |
| ISSN |
1948-5182 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Minireviews |
| Article Title |
Persistent risk for new, subsequent new and recurrent hepatocellular carcinoma despite successful anti-hepatitis B virus therapy and tumor ablation: The need for hepatitis B virus cure
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Brianna J Shinn, Aaron Martin, Robert M Coben, Mitchell I Conn, Jorge Prieto, Howard Kroop, Anthony J DiMarino and Hie-Won Hann |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Hie-Won Hann, Liver Disease Prevention Center, Division of Gastroenterology and Hepatology, Thomas Jefferson University Hospital, 1025 Walnut Street, Philadelphia, PA 19107, United States. hie-won.hann@jefferson.edu |
| Key Words |
Hepatitis B; Hepatocellular carcinoma; Antiviral therapy; Persistent Risk for hepatocellular carcinoma; Tumor ablation |
| Core Tip |
Despite the advances in the management of hepatitis B virus (HBV) infection and HBV-associated hepatocellular carcinoma (HCC), the risk for new, subsequent new and recurrent HCC persists even after over a decade of antiviral therapy and initial tumor ablation. This is due to the inability of the current antiviral therapy to eliminate the cccDNA from the hepatocyte nucleus. There is a great need for an HBV cure drug. |
| Publish Date |
2019-01-27 07:04 |
| Citation |
Shinn BJ, Martin A, Coben RM, Conn MI, Prieto J, Kroop H, DiMarino AJ, Hann HW. Persistent risk for new, subsequent new and recurrent hepatocellular carcinoma despite successful anti-hepatitis B virus therapy and tumor ablation: The need for hepatitis B virus cure. World J Hepatol 2019; 11(1): 65-73 |
| URL |
https://www.wjgnet.com/1948-5182/full/v11/i1/65.htm |
| DOI |
https://dx.doi.org/10.4254/wjh.v11.i1.65 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
